6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
important	JJ	important	important	import	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
and	CC	and	and	and	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Hypotension	NNP	hypotension	hypotension	hypotens	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Impairment	NN	impairment	impairment	impair	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Renal	NNP	renal	renal	renal	N	I-AdverseReaction
Function	NNP	function	function	function	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
with	IN	with	with	with	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
and	CC	and	and	and	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
Secretagogues	NNP	secretagogues	secretagogues	secretagogu	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Genital	NNP	genital	genital	genit	N	B-AdverseReaction
Mycotic	NNP	mycotic	mycotic	mycot	N	I-AdverseReaction
Infections	NNP	infections	infection	infect	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
Tract	NNP	tract	tract	tract	N	I-AdverseReaction
Infections	NNP	infections	infection	infect	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
Low	JJ	low	low	low	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Density	NN	density	density	densiti	N	I-AdverseReaction
Lipoprotein	NNP	lipoprotein	lipoprotein	lipoprotein	N	I-AdverseReaction
Cholesterol	NNP	cholesterol	cholesterol	cholesterol	Y	I-AdverseReaction
(	(	(	(	(	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
C	NNP	c	c	c	N	O
)	)	)	)	)	N	O
[	VBD	[	[	[	N	O
see	JJ	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)]	NN	)]	)]	)]	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
incidence	NN	incidence	incidence	incid	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
and	CC	and	and	and	N	O
female	JJ	female	female	femal	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Boehringer	NNP	boehringer	boehringer	boehring	N	O
Ingelheim	NNP	ingelheim	ingelheim	ingelheim	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
542	CD	542	542	542	N	O
-	:	-	-	-	N	O
6257	CD	6257	6257	6257	N	O
or	CC	or	or	or	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
459	CD	459	459	459	N	O
-	:	-	-	-	N	O
9906	CD	9906	9906	9906	N	O
TTY	NNP	tty	tty	tti	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O
evaluating	VBG	evaluating	evaluating	evalu	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
and	CC	and	and	and	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
are	VBP	are	are	are	N	O
derived	VBN	derived	derived	deriv	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
four	CD	four	four	four	N	O
24	CD	24	24	24	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
18	CD	18	18	18	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
with	IN	with	with	with	N	O
insulin	NN	insulin	insulin	insulin	Y	O
.	.	.	.	.	N	O

JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
was	VBD	was	wa	wa	N	O
used	VBN	used	used	use	N	O
as	IN	as	a	as	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
trial	NN	trial	trial	trial	N	O
and	CC	and	and	and	N	O
as	IN	as	a	as	N	O
add	JJ	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
four	CD	four	four	four	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
data	NNS	data	data	data	N	O
reflect	VBP	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
1976	CD	1976	1976	1976	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
exposure	NN	exposure	exposure	exposur	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
approximately	RB	approximately	approximately	approxim	N	O
23	CD	23	23	23	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
995	CD	995	995	995	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
999	CD	999	999	999	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
977	CD	977	977	977	N	O
)	)	)	)	)	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
56	CD	56	56	56	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
3%	CD	3%	3%	3%	N	O
were	VBD	were	were	were	N	O
older	JJR	older	older	older	N	O
than	IN	than	than	than	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
.	.	.	.	.	N	O

More	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
half	NN	half	half	half	N	O
(	(	(	(	(	N	O
55%	CD	55%	55%	55%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
male	JJ	male	male	male	N	O
;	:	;	;	;	N	O
46%	CD	46%	46%	46%	N	O
were	VBD	were	were	were	N	O
White	NNP	white	white	white	N	O
,	,	,	,	,	N	O
50%	CD	50%	50%	50%	N	O
were	VBD	were	were	were	N	O
Asian	JJ	asian	asian	asian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
3%	CD	3%	3%	3%	N	O
were	VBD	were	were	were	N	O
Black	NNP	black	black	black	N	O
or	CC	or	or	or	N	O
African	JJ	african	african	african	N	O
American	NNP	american	american	american	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
57%	CD	57%	57%	57%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
had	VBD	had	had	had	N	O
diabetes	VBZ	diabetes	diabetes	diabet	Y	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
5	CD	5	5	5	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	O
A1c	NNP	a1c	a1c	a1c	N	O
(	(	(	(	(	N	O
HbA1c	NNP	hba1c	hba1c	hba1c	Y	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
8%	CD	8%	8%	8%	N	O
.	.	.	.	.	N	O

Established	VBN	established	established	establish	N	O
microvascular	JJ	microvascular	microvascular	microvascular	N	O
complications	NNS	complications	complication	complic	N	O
of	IN	of	of	of	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
included	VBD	included	included	includ	N	O
diabetic	JJ	diabetic	diabetic	diabet	Y	O
nephropathy	NN	nephropathy	nephropathy	nephropathi	Y	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
retinopathy	JJ	retinopathy	retinopathy	retinopathi	Y	O
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	O
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
was	VBD	was	wa	wa	N	O
normal	JJ	normal	normal	normal	N	O
or	CC	or	or	or	N	O
mildly	RB	mildly	mildly	mildli	N	O
impaired	VBN	impaired	impaired	impair	N	O
in	IN	in	in	in	N	O
91%	CD	91%	91%	91%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
moderately	RB	moderately	moderately	moder	N	O
impaired	VBN	impaired	impaired	impair	N	O
in	IN	in	in	in	N	O
9%	CD	9%	9%	9%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
mean	JJ	mean	mean	mean	N	O
eGFR	VBP	egfr	egfr	egfr	N	O
86.8	CD	86.8	86.8	86.8	N	O
mL	NNS	ml	ml	ml	N	O
min	RB	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NNS	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
shows	NNS	shows	show	show	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
excluding	VBG	excluding	excluding	exclud	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
)	)	)	)	)	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
present	JJ	present	present	present	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	JJR	more	more	more	N	O
commonly	RB	commonly	commonly	commonli	N	O
on	IN	on	on	on	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
than	IN	than	than	than	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
and	CC	and	and	and	N	O
Greater	NNP	greater	greater	greater	N	O
than	IN	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
Pooled	NNP	pooled	pooled	pool	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
Monotherapy	NNP	monotherapy	monotherapy	monotherapi	N	O
or	CC	or	or	or	N	O
Combination	NNP	combination	combination	combin	N	O
Therapy	NNP	therapy	therapy	therapi	N	O

a	DT	a	a	a	N	O
Predefined	JJ	predefined	predefined	predefin	N	O
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
grouping	NN	grouping	grouping	group	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
not	RB	not	not	not	N	O
limited	JJ	limited	limited	limit	N	O
to	TO	to	to	to	N	O
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
asymptomatic	JJ	asymptomatic	asymptomatic	asymptomat	N	B-AdverseReaction
bacteriuria	NN	bacteriuria	bacteriuria	bacteriuria	Y	I-AdverseReaction
,	,	,	,	,	N	O
cystitis	NN	cystitis	cystitis	cystiti	Y	B-AdverseReaction

b	SYM	b	b	b	N	O
Female	NNP	female	female	femal	N	B-AdverseReaction
genital	JJ	genital	genital	genit	N	I-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
include	VBP	include	include	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
:	:	:	:	:	N	O
vulvovaginal	JJ	vulvovaginal	vulvovaginal	vulvovagin	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
vulvitis	NN	vulvitis	vulvitis	vulviti	Y	B-AdverseReaction
,	,	,	,	,	N	O
vulvovaginal	JJ	vulvovaginal	vulvovaginal	vulvovagin	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
,	,	,	,	,	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
,	,	,	,	,	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
fungal	NN	fungal	fungal	fungal	N	I-AdverseReaction
,	,	,	,	,	N	O
genitourinary	JJ	genitourinary	genitourinary	genitourinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
vulvovaginitis	NN	vulvovaginitis	vulvovaginitis	vulvovagin	Y	B-AdverseReaction
,	,	,	,	,	N	O
cervicitis	NN	cervicitis	cervicitis	cervic	Y	B-AdverseReaction
,	,	,	,	,	N	O
urogenital	JJ	urogenital	urogenital	urogenit	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
fungal	NN	fungal	fungal	fungal	N	I-AdverseReaction
,	,	,	,	,	N	O
vaginitis	NN	vaginitis	vaginitis	vagin	Y	B-AdverseReaction
bacterial	NN	bacterial	bacterial	bacteri	N	I-AdverseReaction
.	.	.	.	.	N	O

Percentages	NNS	percentages	percentage	percentag	N	O
calculated	VBN	calculated	calculated	calcul	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
female	JJ	female	female	femal	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
group	NN	group	group	group	N	O
as	IN	as	a	as	N	O
denominator	NN	denominator	denominator	denomin	N	O
:	:	:	:	:	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
481	CD	481	481	481	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
443	CD	443	443	443	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
420	CD	420	420	420	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

c	NNS	c	c	c	N	O
Predefined	VBD	predefined	predefined	predefin	N	O
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
grouping	NN	grouping	grouping	group	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
not	RB	not	not	not	N	O
limited	JJ	limited	limited	limit	N	O
to	TO	to	to	to	N	O
,	,	,	,	,	N	O
polyuria	NNS	polyuria	polyuria	polyuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
pollakiuria	NN	pollakiuria	pollakiuria	pollakiuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nocturia	NNS	nocturia	nocturia	nocturia	Y	B-AdverseReaction

d	JJ	d	d	d	N	O
Male	NNP	male	male	male	N	O
genital	JJ	genital	genital	genit	N	O
mycotic	JJ	mycotic	mycotic	mycot	N	O
infections	NNS	infections	infection	infect	N	O
include	VBP	include	include	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
:	:	:	:	:	N	O
balanoposthitis	NN	balanoposthitis	balanoposthitis	balanoposth	Y	B-AdverseReaction
,	,	,	,	,	N	O
balanitis	NN	balanitis	balanitis	balan	Y	B-AdverseReaction
,	,	,	,	,	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
fungal	VBP	fungal	fungal	fungal	N	I-AdverseReaction
,	,	,	,	,	N	O
genitourinary	JJ	genitourinary	genitourinary	genitourinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
balanitis	NN	balanitis	balanitis	balan	Y	B-AdverseReaction
candida	NN	candida	candida	candida	N	I-AdverseReaction
,	,	,	,	,	N	O
scrotal	JJ	scrotal	scrotal	scrotal	N	B-AdverseReaction
abscess	NN	abscess	abscess	abscess	Y	I-AdverseReaction
,	,	,	,	,	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
.	.	.	.	.	N	O

Percentages	NNS	percentages	percentage	percentag	N	O
calculated	VBN	calculated	calculated	calcul	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
male	JJ	male	male	male	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
group	NN	group	group	group	N	O
as	IN	as	a	as	N	O
denominator	NN	denominator	denominator	denomin	N	O
:	:	:	:	:	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
514	CD	514	514	514	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
556	CD	556	556	556	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
557	CD	557	557	557	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Number	NNP	number	number	number	N	O

(	(	(	(	(	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O

PlaceboN	NNP	placebon	placebon	placebon	N	O
995	CD	995	995	995	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mgN	NN	mgn	mgn	mgn	N	O
999	CD	999	999	999	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mgN	NN	mgn	mgn	mgn	N	O
977	CD	977	977	977	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
a	DT	a	a	a	N	O
7.6%	CD	7.6%	7.6%	7.6%	N	O
9.3%	CD	9.3%	9.3%	9.3%	N	O
7.6%	CD	7.6%	7.6%	7.6%	N	O

Female	NNP	female	female	femal	N	B-AdverseReaction
genital	JJ	genital	genital	genit	N	I-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
b	VBP	b	b	b	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
5.4%	CD	5.4%	5.4%	5.4%	N	O
6.4%	CD	6.4%	6.4%	6.4%	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
3.8%	CD	3.8%	3.8%	3.8%	N	O
3.1%	CD	3.1%	3.1%	3.1%	N	O
4.0%	CD	4.0%	4.0%	4.0%	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
urination	NN	urination	urination	urin	N	I-AdverseReaction
c	VBZ	c	c	c	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
3.4%	CD	3.4%	3.4%	3.4%	N	O
3.2%	CD	3.2%	3.2%	3.2%	N	O

Dyslipidemia	NNP	dyslipidemia	dyslipidemia	dyslipidemia	Y	B-AdverseReaction
3.4%	CD	3.4%	3.4%	3.4%	N	O
3.9%	CD	3.9%	3.9%	3.9%	N	O
2.9%	CD	2.9%	2.9%	2.9%	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
2.2%	CD	2.2%	2.2%	2.2%	N	O
2.4%	CD	2.4%	2.4%	2.4%	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O

Male	JJ	male	male	male	N	B-AdverseReaction
genital	JJ	genital	genital	genit	N	I-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
d	VBP	d	d	d	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
3.1%	CD	3.1%	3.1%	3.1%	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
1.4%	CD	1.4%	1.4%	1.4%	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O

Thirst	NNP	thirst	thirst	thirst	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
polydipsia	NN	polydipsia	polydipsia	polydipsia	Y	B-AdverseReaction
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0%	CD	0%	0%	0%	N	O
,	,	,	,	,	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Volume	NN	volume	volume	volum	N	O

Depletion	NN	depletion	depletion	deplet	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
causes	VBZ	causes	cause	caus	N	O
an	DT	an	an	an	N	O
osmotic	JJ	osmotic	osmotic	osmot	N	B-AdverseReaction
diuresis	NN	diuresis	diuresis	diuresi	Y	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
intravascular	JJ	intravascular	intravascular	intravascular	N	B-AdverseReaction
volume	NN	volume	volume	volum	N	I-AdverseReaction
contraction	NN	contraction	contraction	contract	N	I-AdverseReaction
and	CC	and	and	and	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
volume	NN	volume	volume	volum	N	B-AdverseReaction
depletion	NN	depletion	depletion	deplet	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
five	CD	five	five	five	N	O
placebo	NNS	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
volume	NN	volume	volume	volum	N	B-AdverseReaction
depletion	NN	depletion	depletion	deplet	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
(	(	(	(	(	N	O
ambulatory	NN	ambulatory	ambulatory	ambulatori	N	O
)	)	)	)	)	N	O
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
systolic	NN	systolic	systolic	systol	N	I-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypovolemia	NN	hypovolemia	hypovolemia	hypovolemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
orthostatic	JJ	orthostatic	orthostatic	orthostat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
,	,	,	,	,	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
volume	NN	volume	volume	volum	N	O
contraction	NN	contraction	contraction	contract	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.5	CD	8.5	8.5	8.5	N	O
,	,	,	,	,	N	O
8.6	CD	8.6	8.6	8.6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
Urination	NN	urination	urination	urin	N	I-AdverseReaction
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
five	CD	five	five	five	N	O
placebo	NNS	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
increased	JJ	increased	increased	increas	N	B-AdverseReaction
urination	NN	urination	urination	urin	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
polyuria	NN	polyuria	polyuria	polyuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
pollakiuria	NN	pollakiuria	pollakiuria	pollakiuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nocturia	NNS	nocturia	nocturia	nocturia	Y	B-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
on	IN	on	on	on	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
than	IN	than	than	than	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Specifically	RB	specifically	specifically	specif	N	O
,	,	,	,	,	N	O
nocturia	NN	nocturia	nocturia	nocturia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
,	,	,	,	,	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Impairment	NN	impairment	impairment	impair	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Renal	NNP	renal	renal	renal	N	I-AdverseReaction
Function	NNP	function	function	function	N	I-AdverseReaction
Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
decreases	NNS	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
eGFR	NN	egfr	egfr	egfr	N	I-AdverseReaction
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
had	VBD	had	had	had	N	O
larger	JJR	larger	larger	larger	N	O
mean	JJ	mean	mean	mean	N	O
changes	NNS	changes	change	chang	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.5	CD	8.5	8.5	8.5	N	O
,	,	,	,	,	N	O
8.6	CD	8.6	8.6	8.6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
Changes	NNS	changes	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	O
Serum	NNP	serum	serum	serum	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
and	CC	and	and	and	N	O
eGFR	NN	egfr	egfr	egfr	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Pool	NNP	pool	pool	pool	N	O
of	IN	of	of	of	N	O
Four	NNP	four	four	four	N	O
24	CD	24	24	24	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBN	controlled	controlled	control	N	O
Studies	NNS	studies	study	studi	N	O
and	CC	and	and	and	N	O
Renal	NNP	renal	renal	renal	N	O
Impairment	NNP	impairment	impairment	impair	N	O
Study	NNP	study	study	studi	N	O

a	DT	a	a	a	N	O
Subset	NNP	subset	subset	subset	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
from	IN	from	from	from	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
eGFR	$	egfr	egfr	egfr	N	B-AdverseReaction
30	CD	30	30	30	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
less	JJR	less	le	less	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
60	CD	60	60	60	N	I-AdverseReaction
mL	JJ	ml	ml	ml	N	I-AdverseReaction
min	NN	min	min	min	N	I-AdverseReaction
1.73	CD	1.73	1.73	1.73	N	I-AdverseReaction
m	NN	m	m	m	N	I-AdverseReaction
2	CD	2	2	2	N	I-AdverseReaction

Pool	NN	pool	pool	pool	N	O

of	IN	of	of	of	N	O
24	CD	24	24	24	N	O
-	:	-	-	-	N	O
Week	NN	week	week	week	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Studies	NNS	studies	study	studi	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
Mean	NNP	mean	mean	mean	N	O
N	NNP	n	n	n	N	O
825	CD	825	825	825	N	O
830	CD	830	830	830	N	O
822	CD	822	822	822	N	O

Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.84	CD	0.84	0.84	0.84	N	O
0.85	CD	0.85	0.85	0.85	N	O
0.85	CD	0.85	0.85	0.85	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
87.3	CD	87.3	87.3	87.3	N	O
87.1	CD	87.1	87.1	87.1	N	O
87.8	CD	87.8	87.8	87.8	N	O

Week	JJ	week	week	week	N	O
12	CD	12	12	12	N	O
Change	NNP	change	change	chang	N	O
N	NNP	n	n	n	N	O
771	CD	771	771	771	N	O
797	CD	797	797	797	N	O
783	CD	783	783	783	N	O

Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.00	CD	0.00	0.00	0.00	N	O
0.02	CD	0.02	0.02	0.02	N	O
0.01	CD	0.01	0.01	0.01	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
0.3	CD	0.3	0.3	0.3	N	O
-	:	-	-	-	N	O
1.3	CD	1.3	1.3	1.3	N	O
-	:	-	-	-	N	O
1.4	CD	1.4	1.4	1.4	N	O

Week	JJ	week	week	week	N	O
24	CD	24	24	24	N	O
Change	NNP	change	change	chang	N	O
N	NNP	n	n	n	N	O
708	CD	708	708	708	N	O
769	CD	769	769	769	N	O
754	CD	754	754	754	N	O

Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.00	CD	0.00	0.00	0.00	N	O
0.01	CD	0.01	0.01	0.01	N	O
0.01	CD	0.01	0.01	0.01	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
0.3	CD	0.3	0.3	0.3	N	O
-	:	-	-	-	N	O
0.6	CD	0.6	0.6	0.6	N	O
-	:	-	-	-	N	O
1.4	CD	1.4	1.4	1.4	N	O

Moderate	NNP	moderate	moderate	moder	N	O
Renal	NNP	renal	renal	renal	N	O
Impairment	NNP	impairment	impairment	impair	N	O
a	DT	a	a	a	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
N	NNP	n	n	n	N	O
187	CD	187	187	187	N	O
--	:	--	--	--	N	O
187	CD	187	187	187	N	O

Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
1.49	CD	1.49	1.49	1.49	N	O
--	:	--	--	--	N	O
1.46	CD	1.46	1.46	1.46	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
44.3	CD	44.3	44.3	44.3	N	O
--	:	--	--	--	N	O
45.4	CD	45.4	45.4	45.4	N	O

Week	JJ	week	week	week	N	O
12	CD	12	12	12	N	O
Change	NNP	change	change	chang	N	O
N	NNP	n	n	n	N	O
176	CD	176	176	176	N	O
--	:	--	--	--	N	O
179	CD	179	179	179	N	O

Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.01	CD	0.01	0.01	0.01	N	O
--	:	--	--	--	N	O
0.12	CD	0.12	0.12	0.12	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
0.1	CD	0.1	0.1	0.1	N	O
--	:	--	--	--	N	O
-	:	-	-	-	N	O
3.8	CD	3.8	3.8	3.8	N	O

Week	JJ	week	week	week	N	O
24	CD	24	24	24	N	O
Change	NNP	change	change	chang	N	O
N	NNP	n	n	n	N	O
170	CD	170	170	170	N	O
--	:	--	--	--	N	O
171	CD	171	171	171	N	O

Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.01	CD	0.01	0.01	0.01	N	O
--	:	--	--	--	N	O
0.10	CD	0.10	0.10	0.10	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
0.2	CD	0.2	0.2	0.2	N	O
--	:	--	--	--	N	O
-	:	-	-	-	N	O
3.2	CD	3.2	3.2	3.2	N	O

Week	JJ	week	week	week	N	O
52	CD	52	52	52	N	O
Change	NNP	change	change	chang	N	O
N	NNP	n	n	n	N	O
164	CD	164	164	164	N	O
--	:	--	--	--	N	O
162	CD	162	162	162	N	O

Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.02	CD	0.02	0.02	0.02	N	O
--	:	--	--	--	N	O
0.11	CD	0.11	0.11	0.11	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
0.3	CD	0.3	0.3	0.3	N	O
--	:	--	--	--	N	O
-	:	-	-	-	N	O
2.8	CD	2.8	2.8	2.8	N	O

Hypoglycemia	NNP	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
by	IN	by	by	by	N	O
study	NN	study	study	studi	N	O
is	VBZ	is	is	is	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	O
when	WRB	when	when	when	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
was	VBD	was	wa	wa	N	O
administered	VBN	administered	administered	administ	N	O
with	IN	with	with	with	N	O
insulin	NN	insulin	insulin	insulin	Y	O
or	CC	or	or	or	N	O
sulfonylurea	JJ	sulfonylurea	sulfonylurea	sulfonylurea	N	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

3	CD	3	3	3	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Overalla	NNP	overalla	overalla	overalla	N	O
and	CC	and	and	and	N	O
Severeb	NNP	severeb	severeb	severeb	N	B-Severity
Hypoglycemic	NNP	hypoglycemic	hypoglycemic	hypoglycem	N	B-AdverseReaction
Events	NNS	events	event	event	N	I-AdverseReaction
in	IN	in	in	in	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNS	studies	study	studi	N	O

a	DT	a	a	a	N	O
Overall	JJ	overall	overall	overal	N	O
hypoglycemic	JJ	hypoglycemic	hypoglycemic	hypoglycem	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
:	:	:	:	:	N	O
plasma	NN	plasma	plasma	plasma	N	B-AdverseReaction
or	CC	or	or	or	N	O
capillary	JJ	capillary	capillary	capillari	N	B-AdverseReaction
glucose	NN	glucose	glucose	glucos	Y	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
less	JJR	less	le	less	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
or	CC	or	or	or	N	I-AdverseReaction
equal	JJ	equal	equal	equal	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
70	CD	70	70	70	N	I-AdverseReaction
mg	NNS	mg	mg	mg	N	I-AdverseReaction
dL	NN	dl	dl	dl	N	I-AdverseReaction

b	NN	b	b	b	N	O
Severe	NNP	severe	severe	sever	N	B-Severity
hypoglycemic	JJ	hypoglycemic	hypoglycemic	hypoglycem	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
:	:	:	:	:	N	O
requiring	VBG	requiring	requiring	requir	N	O
assistance	NN	assistance	assistance	assist	N	O
regardless	NN	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
blood	NN	blood	blood	blood	N	O
glucose	NN	glucose	glucose	glucos	Y	O

c	JJ	c	c	c	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
dose	NN	dose	dose	dose	N	O
could	MD	could	could	could	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
adjusted	VBN	adjusted	adjusted	adjust	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
initial	JJ	initial	initial	initi	N	O
18	CD	18	18	18	N	O
week	NN	week	week	week	N	O
treatment	NN	treatment	treatment	treatment	N	O
period	NN	period	period	period	N	O

Monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O

(	(	(	(	(	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
229	CD	229	229	229	N	O
)	)	)	)	)	N	O
JARDIANCE	$	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
224	CD	224	224	224	N	O
)	)	)	)	)	N	O
JARDIANCE	$	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
223	CD	223	223	223	N	O
)	)	)	)	)	N	O

Overall	NNP	overall	overall	overal	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O

Severe	NNP	severe	severe	sever	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
0%	CD	0%	0%	0%	N	O
0%	CD	0%	0%	0%	N	O
0%	CD	0%	0%	0%	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
withMetformin	NN	withmetformin	withmetformin	withmetformin	N	O
(	(	(	(	(	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
206	CD	206	206	206	N	O
)	)	)	)	)	N	O
JARDIANCE	$	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
217	CD	217	217	217	N	O
)	)	)	)	)	N	O
JARDIANCE	$	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
214	CD	214	214	214	N	O
)	)	)	)	)	N	O

Overall	NNP	overall	overall	overal	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
1.4%	CD	1.4%	1.4%	1.4%	N	O

Severe	NNP	severe	severe	sever	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
0%	CD	0%	0%	0%	N	O
0%	CD	0%	0%	0%	N	O
0%	CD	0%	0%	0%	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
withMetformin	NNP	withmetformin	withmetformin	withmetformin	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
225	CD	225	225	225	N	O
)	)	)	)	)	N	O
JARDIANCE	$	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
224	CD	224	224	224	N	O
)	)	)	)	)	N	O
JARDIANCE	$	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
217	CD	217	217	217	N	O
)	)	)	)	)	N	O

Overall	NNP	overall	overall	overal	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
8.4%	CD	8.4%	8.4%	8.4%	N	O
16.1%	CD	16.1%	16.1%	16.1%	N	O
11.5%	CD	11.5%	11.5%	11.5%	N	O

Severe	NNP	severe	severe	sever	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
0%	CD	0%	0%	0%	N	O
0%	CD	0%	0%	0%	N	O
0%	CD	0%	0%	0%	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
withPioglitazone	SYM	withpioglitazone	withpioglitazone	withpioglitazon	N	O
-	:	-	-	-	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
165	CD	165	165	165	N	O
)	)	)	)	)	N	O
JARDIANCE	$	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
Pioglitazone	NNP	pioglitazone	pioglitazone	pioglitazon	N	O
-	:	-	-	-	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
165	CD	165	165	165	N	O
)	)	)	)	)	N	O
JARDIANCE	$	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
Pioglitazone	NNP	pioglitazone	pioglitazone	pioglitazon	N	O
-	:	-	-	-	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
168	CD	168	168	168	N	O
)	)	)	)	)	N	O

Overall	NNP	overall	overall	overal	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
2.4%	CD	2.4%	2.4%	2.4%	N	O

Severe	NNP	severe	severe	sever	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
0%	CD	0%	0%	0%	N	O
0%	CD	0%	0%	0%	N	O
0%	CD	0%	0%	0%	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Basal	NNP	basal	basal	basal	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
weeks	NNS	weeks	week	week	N	O
c	NN	c	c	c	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
170	CD	170	170	170	N	O
)	)	)	)	)	N	O
JARDIANCE	$	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
169	CD	169	169	169	N	O
)	)	)	)	)	N	O
JARDIANCE	$	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
155	CD	155	155	155	N	O
)	)	)	)	)	N	O

Overall	NNP	overall	overall	overal	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
20.6%	CD	20.6%	20.6%	20.6%	N	O
19.5%	CD	19.5%	19.5%	19.5%	N	O
28.4%	CD	28.4%	28.4%	28.4%	N	O

Severe	NNP	severe	severe	sever	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
0%	CD	0%	0%	0%	N	O
0%	CD	0%	0%	0%	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
MDI	NNP	mdi	mdi	mdi	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
-	:	-	-	-	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
weeks	NNS	weeks	week	week	N	O
c	NN	c	c	c	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
188	CD	188	188	188	N	O
)	)	)	)	)	N	O
JARDIANCE	$	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
186	CD	186	186	186	N	O
)	)	)	)	)	N	O
JARDIANCE	$	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
189	CD	189	189	189	N	O
)	)	)	)	)	N	O

Overall	NNP	overall	overall	overal	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
37.2%	CD	37.2%	37.2%	37.2%	N	O
39.8%	CD	39.8%	39.8%	39.8%	N	O
41.3%	CD	41.3%	41.3%	41.3%	N	O

Severe	NNP	severe	severe	sever	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O

Genital	NNP	genital	genital	genit	N	B-AdverseReaction
Mycotic	NNP	mycotic	mycotic	mycot	N	I-AdverseReaction
Infections	NNP	infections	infection	infect	N	I-AdverseReaction
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
five	CD	five	five	five	N	O
placebo	NNS	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
fungal	NN	fungal	fungal	fungal	N	I-AdverseReaction
,	,	,	,	,	N	O
vulvovaginal	JJ	vulvovaginal	vulvovaginal	vulvovagin	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vulvitis	NN	vulvitis	vulvitis	vulviti	Y	B-AdverseReaction
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
increased	VBN	increased	increased	increas	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
,	,	,	,	,	N	O
4.1%	CD	4.1%	4.1%	4.1%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
3.7%	CD	3.7%	3.7%	3.7%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
from	IN	from	from	from	N	O
study	NN	study	study	studi	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0%	CD	0%	0%	0%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
either	DT	either	either	either	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
or	CC	or	or	or	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

Genital	NN	genital	genital	genit	N	B-AdverseReaction

mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
female	NN	female	female	femal	N	O
than	IN	than	than	than	N	O
male	JJ	male	male	male	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Phimosis	NN	phimosis	phimosis	phimosi	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
male	NN	male	male	male	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
JARDIANCE	$	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
)	)	)	)	)	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
Tract	NNP	tract	tract	tract	N	I-AdverseReaction
Infections	NNP	infections	infection	infect	N	I-AdverseReaction
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
five	CD	five	five	five	N	O
placebo	NNS	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
asymptomatic	JJ	asymptomatic	asymptomatic	asymptomat	N	B-AdverseReaction
bacteriuria	NN	bacteriuria	bacteriuria	bacteriuria	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
cystitis	NN	cystitis	cystitis	cystiti	Y	B-AdverseReaction
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
increased	VBN	increased	increased	increas	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
chronic	NN	chronic	chronic	chronic	N	O
or	CC	or	or	or	N	O
recurrent	NN	recurrent	recurrent	recurr	N	O
urinary	JJ	urinary	urinary	urinari	N	O
tract	NN	tract	tract	tract	N	O
infections	NNS	infections	infection	infect	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
experience	VB	experience	experience	experi	N	O
a	DT	a	a	a	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
,	,	,	,	,	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
female	JJ	female	female	femal	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
in	IN	in	in	in	N	O
female	JJ	female	female	femal	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
was	VBD	was	wa	wa	N	O
16.6%	CD	16.6%	16.6%	16.6%	N	O
,	,	,	,	,	N	O
18.4%	CD	18.4%	18.4%	18.4%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
17.0%	CD	17.0%	17.0%	17.0%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
in	IN	in	in	in	N	O
male	JJ	male	male	male	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
was	VBD	was	wa	wa	N	O
3.2%	CD	3.2%	3.2%	3.2%	N	O
,	,	,	,	,	N	O
3.6%	CD	3.6%	3.6%	3.6%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
4.1%	CD	4.1%	4.1%	4.1%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.5	CD	8.5	8.5	8.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
Tests	NNS	tests	test	test	N	O
Increase	NNP	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Low	NNP	low	low	low	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Density	NN	density	density	densiti	N	I-AdverseReaction
Lipoprotein	NNP	lipoprotein	lipoprotein	lipoprotein	N	I-AdverseReaction
Cholesterol	NNP	cholesterol	cholesterol	cholesterol	Y	I-AdverseReaction
(	(	(	(	(	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
C	NNP	c	c	c	N	O
)	)	)	)	)	N	O
Dose	NNP	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
low	JJ	low	low	low	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
density	NN	density	density	densiti	N	I-AdverseReaction
lipoprotein	NN	lipoprotein	lipoprotein	lipoprotein	N	I-AdverseReaction
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	I-AdverseReaction
(	(	(	(	(	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
C	NN	c	c	c	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
.	.	.	.	.	N	O

LDL	NNP	ldl	ldl	ldl	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
C	NN	c	c	c	N	I-AdverseReaction
increased	VBN	increased	increased	increas	N	I-AdverseReaction
by	IN	by	by	by	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
,	,	,	,	,	N	O
4.6%	CD	4.6%	4.6%	4.6%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
6.5%	CD	6.5%	6.5%	6.5%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
range	NN	range	range	rang	N	O
of	IN	of	of	of	N	O
mean	JJ	mean	mean	mean	N	O
baseline	NN	baseline	baseline	baselin	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
C	NN	c	c	c	N	O
levels	NNS	levels	level	level	N	O
was	VBD	was	wa	wa	N	O
90.3	CD	90.3	90.3	90.3	N	O
to	TO	to	to	to	N	O
90.6	CD	90.6	90.6	90.6	N	O
mg	NNS	mg	mg	mg	N	O
dL	JJ	dl	dl	dl	N	O
across	IN	across	across	across	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

Increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Hematocrit	NNP	hematocrit	hematocrit	hematocrit	Y	I-AdverseReaction
In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
four	CD	four	four	four	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	JJ	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
median	JJ	median	median	median	N	O
hematocrit	NN	hematocrit	hematocrit	hematocrit	Y	B-AdverseReaction
decreased	VBN	decreased	decreased	decreas	N	I-AdverseReaction
by	IN	by	by	by	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	B-Factor
and	CC	and	and	and	N	O
increased	VBN	increased	increased	increas	N	I-AdverseReaction
by	IN	by	by	by	N	O
2.8%	CD	2.8%	2.8%	2.8%	N	O
in	IN	in	in	in	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
2.8%	CD	2.8%	2.8%	2.8%	N	O
in	IN	in	in	in	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
the	DT	the	the	the	N	O
end	NN	end	end	end	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
,	,	,	,	,	N	O
2.7%	CD	2.7%	2.7%	2.7%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
3.5%	CD	3.5%	3.5%	3.5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
hematocrits	NNS	hematocrits	hematocrit	hematocrit	N	O
initially	RB	initially	initially	initi	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
reference	NN	reference	reference	refer	N	O
range	NN	range	range	rang	N	O
had	VBD	had	had	had	N	O
values	NNS	values	value	valu	N	O
above	IN	above	above	abov	N	O
the	DT	the	the	the	N	O
upper	JJ	upper	upper	upper	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
reference	NN	reference	reference	refer	N	O
range	NN	range	range	rang	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
:	:	:	:	:	N	O
Before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
assess	NN	assess	ass	assess	N	O
and	CC	and	and	and	N	O
correct	JJ	correct	correct	correct	N	O
volume	NN	volume	volume	volum	N	O
status	NN	status	status	statu	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
low	JJ	low	low	low	N	O
systolic	JJ	systolic	systolic	systol	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
diuretics	NNS	diuretics	diuretic	diuret	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Impairment	NN	impairment	impairment	impair	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

More	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
eGFR	JJ	egfr	egfr	egfr	N	O
below	IN	below	below	below	N	O
60	CD	60	60	60	N	O
mL	NNS	ml	ml	ml	N	O
min	RB	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NNS	m	m	m	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
:	:	:	:	:	N	O
Consider	VB	consider	consider	consid	N	O
lowering	VBG	lowering	lowering	lower	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogue	NN	secretagogue	secretagogue	secretagogu	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
when	WRB	when	when	when	N	O
initiating	VBG	initiating	initiating	initi	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Genital	NNP	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
as	IN	as	a	as	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
as	IN	as	a	as	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
LDL	NNP	ldl	ldl	ldl	Y	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
C	NN	c	c	c	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
as	IN	as	a	as	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
outcomes	NNS	outcomes	outcome	outcom	N	O
:	:	:	:	:	N	O
There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
no	DT	no	no	no	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
establishing	VBG	establishing	establishing	establish	N	O
conclusive	JJ	conclusive	conclusive	conclus	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
risk	NN	risk	risk	risk	N	O
reduction	NN	reduction	reduction	reduct	N	O
with	IN	with	with	with	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Hypotension	NN	hypotension	hypotension	hypotens	Y	O

JARDIANCE	NN	jardiance	jardiance	jardianc	N	O

causes	NNS	causes	cause	caus	N	O
intravascular	JJ	intravascular	intravascular	intravascular	N	B-AdverseReaction
volume	NN	volume	volume	volum	N	I-AdverseReaction
contraction	NN	contraction	contraction	contract	N	I-AdverseReaction
.	.	.	.	.	N	O

Symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
after	IN	after	after	after	N	O
initiating	VBG	initiating	initiating	initi	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	RB	)]	)]	)]	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
low	JJ	low	low	low	N	O
systolic	JJ	systolic	systolic	systol	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
diuretics	NNS	diuretics	diuretic	diuret	N	O
.	.	.	.	.	N	O

Before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
,	,	,	,	,	N	O
assess	NN	assess	ass	assess	N	O
for	IN	for	for	for	N	O
volume	NN	volume	volume	volum	N	O
contraction	NN	contraction	contraction	contract	N	O
and	CC	and	and	and	N	O
correct	JJ	correct	correct	correct	N	O
volume	NN	volume	volume	volum	N	O
status	NN	status	status	statu	N	O
if	IN	if	if	if	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
after	IN	after	after	after	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
increase	VB	increase	increase	increas	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
situations	NNS	situations	situation	situat	N	O
where	WRB	where	where	where	N	O
volume	NN	volume	volume	volum	N	O
contraction	NN	contraction	contraction	contract	N	O
is	VBZ	is	is	is	N	O
expected	VBN	expected	expected	expect	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.5	CD	8.5	8.5	8.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Impairment	NNP	impairment	impairment	impair	N	O
in	IN	in	in	in	N	O
Renal	NNP	renal	renal	renal	N	O
Function	NNP	function	function	function	N	O

JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
increases	VBZ	increases	increase	increas	N	B-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
decreases	VBZ	decreases	decrease	decreas	N	B-AdverseReaction
eGFR	JJ	egfr	egfr	egfr	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
impaired	JJ	impaired	impaired	impair	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
with	IN	with	with	with	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
is	VBZ	is	is	is	N	O
increased	VBN	increased	increased	increas	N	O
in	IN	in	in	in	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
.	.	.	.	.	N	O

More	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.5	CD	8.5	8.5	8.5	N	O
,	,	,	,	,	N	O
8.6	CD	8.6	8.6	8.6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Hypoglycemia	NNP	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
with	IN	with	with	with	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
and	CC	and	and	and	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
Secretagogues	NNP	secretagogues	secretagogues	secretagogu	N	O

Insulin	NNP	insulin	insulin	insulin	Y	O
and	CC	and	and	and	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogues	NNS	secretagogues	secretagogues	secretagogu	N	O
are	VBP	are	are	are	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
is	VBZ	is	is	is	N	O
increased	VBN	increased	increased	increas	N	O
when	WRB	when	when	when	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogues	NNS	secretagogues	secretagogues	secretagogu	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
sulfonylurea	NN	sulfonylurea	sulfonylurea	sulfonylurea	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
insulin	JJ	insulin	insulin	insulin	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogue	NN	secretagogue	secretagogue	secretagogu	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
required	VBN	required	required	requir	N	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
when	WRB	when	when	when	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Genital	NNP	genital	genital	genit	N	O
Mycotic	NNP	mycotic	mycotic	mycot	N	O
Infections	NNP	infections	infection	infect	N	O

JARDIANCE	NN	jardiance	jardiance	jardianc	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
chronic	NN	chronic	chronic	chronic	N	O
or	CC	or	or	or	N	O
recurrent	NN	recurrent	recurrent	recurr	N	O
genital	JJ	genital	genital	genit	N	O
mycotic	JJ	mycotic	mycotic	mycot	N	O
infections	NNS	infections	infection	infect	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
develop	VB	develop	develop	develop	N	O
mycotic	JJ	mycotic	mycotic	mycot	N	B-AdverseReaction
genital	JJ	genital	genital	genit	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
as	IN	as	a	as	N	O
appropriate	NN	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Urinary	JJ	urinary	urinary	urinari	N	O
Tract	NNP	tract	tract	tract	N	O
Infections	NNP	infections	infection	infect	N	O

JARDIANCE	NN	jardiance	jardiance	jardianc	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
as	IN	as	a	as	N	O
appropriate	NN	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Increased	VBD	increased	increased	increas	N	O
Low	NNP	low	low	low	N	O
-	:	-	-	-	N	O
Density	NN	density	density	densiti	N	O
Lipoprotein	NNP	lipoprotein	lipoprotein	lipoprotein	N	O
Cholesterol	NNP	cholesterol	cholesterol	cholesterol	Y	O
(	(	(	(	(	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
C	NN	c	c	c	N	O
)	)	)	)	)	N	O

Increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
LDL	NNP	ldl	ldl	ldl	Y	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
C	NN	c	c	c	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
with	IN	with	with	with	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
as	IN	as	a	as	N	O
appropriate	NN	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
Outcomes	NNS	outcomes	outcome	outcom	N	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
no	DT	no	no	no	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
establishing	VBG	establishing	establishing	establish	N	O
conclusive	JJ	conclusive	conclusive	conclus	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
risk	NN	risk	risk	risk	N	O
reduction	NN	reduction	reduction	reduct	N	O
with	IN	with	with	with	N	O
JARDIANCE	NNP	jardiance	jardiance	jardianc	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

